The computations for this study are based on individual data from the Swedish Inpatient register held by the National Board of Health and Welfare which are not publicly available. All personal data are subjected to secrecy in accordance with the Swedish Public Access to Information and Secrecy Act (OSL, 2009:400). The dataset can be made available to researchers upon request pending approval by the appropriate ethics committee. Formal requests of the data should be made to <http://www.socialstyrelsen.se/statistics> which can also provide information about the register and persons to contact for queries. All relevant aggregated data on number of cases per year, age and gender are already contained within the paper, supporting information files and its supporting information. Population data are available at Human Mortality Database at [www.mortality.org](http://www.mortality.org).

Introduction {#sec005}
============

In 2015, stroke-related disease caused more than 6 million deaths worldwide and is considered as one of the most common causes of death and disability among adults \[[@pone.0179658.ref001],[@pone.0179658.ref002]\] For the past 2 decades a significant decline in overall mortality and incidence of stroke have been observed in many West European countries \[[@pone.0179658.ref003]--[@pone.0179658.ref006]\]. In Sweden, the incidence of ischemic stroke (IS) has decreased among older people, but increased among younger adults (\<45 years) \[[@pone.0179658.ref007]\]. The underlying causes for this trend are not well understood, but are of major concern if those who are young carry this increase with them as they age, which will put additional strain on the healthcare system. Therefore, information regarding occurrence of stroke is important for planning of future strategies in prevention and care.

The absolute number of cases of stroke is expected to increase in the near future because of the growing older population. According to a recent report from Canada, the projected number of people experiencing effects of stroke will increase by between 62% and 79% from 2013 to 2038 \[[@pone.0179658.ref008]\]. Similar projections have been reported in other regions, including Western Australia and United States, with an overall increase in prevalence over time \[[@pone.0179658.ref009],[@pone.0179658.ref010]\]. In Sweden, the majority of all stroke cases (\~85%) are ischemic stroke (IS), but trends and current prevalence of IS have not been well quantified in the Swedish population. The present study aimed to investigate age- and sex-specific time trends of the prevalence and absolute number of IS survivors in Sweden from 1995--2010.

Materials and methods {#sec006}
=====================

Study population {#sec007}
----------------

In Sweden, a universal health care system is provided at a low cost to all citizens. Hospitals are required to report the principal and contributory diagnosis to the Inpatient Register (IPR) and the Cause of Death Register. The IPR was established in 1964 and has been operating on a national basis since 1987 with a complete national coverage of all hospital discharge diagnoses, while the Cause of Death Register has been in operation since 1961. For the purpose of this study, data were obtained by linkage with the IPR and Cause of Death Register through the Swedish 10-digit personal identifier.

In the present study, all men and women older than 18 years who were hospitalized at least once during 1995--2010 and survived with a principal discharge diagnosis of IS were included. Patients were stratified according to age group (18--44, 45--54, 55--64, 65--74, 75--84, and ≥85 years) and admission years. All discharge diagnoses were coded according to the International Classification of Disease (ICD) system. The ICD-8 was used from 1968 to 1987, ICD-9 from 1987 to 1996, and ICD-10 from 1996 onwards. Ischemic stroke was coded as ICD-8 and ICD-9 code 434 and 436 and ICD-10 codes I63 and I64.

Administrative data from the Swedish IPR and Cause of Death register was used to estimate the prevalence of IS over time for a specific age and year. The prevalence of IS includes 2 subsets of prevalent cases: 1) incident cases that survive up to an index date and 2) cases that were incident before the start of the registry and survived up to the index date. The second data set was created using the mean incidence rate from the IPR to estimate the annual number of incident cases for each age and sex. All survival estimates before 1987 were adjusted to follow the mortality rate in the general population. The counting method used to accumulate prevalent cases of IS for the datasets was described more formally by Gail et al \[[@pone.0179658.ref011]\]. The Swedish general population from Human Mortality Database was used as the reference group when calculating the prevalence of IS in the population \[[@pone.0179658.ref012]\]. Prevalence is reported as patients per 10,000 population.

Statistical analysis {#sec008}
--------------------

Prevalence and survival were estimated by SAS software version 9.3 (SAS, Cary, NC, USA) and R program version 2X. Joinpoint regression analysis was performed with Joinpoint Regression Program 4.2.0.2 (Statistical Methodology and Applications Branch, Surveillance Research Program, National Cancer Institute). The prevalence (proportions) was used as dependent variable and year (1995--2010) was used as independent variable, the analysis was stratified by age group. A linear model with minimum four data point between each jointpoint and a maximum of 2 joinpoints were allowed in which the software finds the optimal number of joinpoints. The slopes (S) and intercepts were estimated using least squares and the number and position of the joinpoints were automatically selected using grid search. Within each interval, the APC were calculated as: (exp (Si)-1)\*100, and the average APC (AAPC) were calculated from the weighted average (with number of data points within each interval as weight) of slopes. The upper and lower 95% confidence interval (CI) for the APC within each interval was calculated from the estimated variances of the slopes (Vi): (exp(Si+/-t\*Vi-1)\*100, and the 95% CI of the AAPC was calculated from the pooled variance and average slope.

Ethics statement {#sec009}
----------------

This study was approved by the Regional Ethical Review Board of Gothenburg University (number 540--11). For anonymity, all personal identifiers were removed and replaced with a code in the final data set.

Results {#sec010}
-------

From 1995--2010, the number of patients with IS aged 18 to ≥85 years in Sweden increased from 129,418 to 148,778. The number of male patients increased from 70,958 to 79,817 and that of female patients increased from 58,460 to 68,961, corresponding to a relative increase of 12.5% and 18.0%, respectively ([S1 Table](#pone.0179658.s003){ref-type="supplementary-material"}). The largest relative increase was observed in age groups 55--64 years and ≥85 years, by 49% and 28%, respectively, in men and 61% and 47%, respectively, in women ([S1B Fig](#pone.0179658.s001){ref-type="supplementary-material"} for men and [S1C Fig](#pone.0179658.s001){ref-type="supplementary-material"} for women). During the same period there was an approximate increase of \~40% in the total population size among those aged 55--64 years and ≥85 years ([S2 Fig](#pone.0179658.s002){ref-type="supplementary-material"}).

Overall prevalence {#sec011}
------------------

[Table 1](#pone.0179658.t001){ref-type="table"} shows the prevalence of IS in the total population and [Table 2](#pone.0179658.t002){ref-type="table"} the joinpoint analysis of trends in prevalence in Sweden by age, sex and year. The overall prevalence of surviving patients who had ever been hospitalized with IS aged 18 to ≥85 years was 189 patients per 10,000 population in 1995, which increased to 202 patients per 10,000 population in 2000 with an APC of 1.6% (95% CI 1.4 to 1.7). The prevalence remained stable until 2006, followed by a decrease (APC: -0.8%, 95% CI -1.0 to -0.6) and with a final prevalence of 199 patients per 10,000 population in 2010.

10.1371/journal.pone.0179658.t001

###### Prevalence of patients hospitalized with ischemic stroke in the total population divided by age groups, sex and calendar year from 1995--2010.

![](pone.0179658.t001){#pone.0179658.t001g}

  Age group (years), Prevalence per 10,000 population   1995   1996   1997   1998   1999   2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010
  ----------------------------------------------------- ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------
  [**Overall**]{.ul}                                                                                                                                             
  18--44                                                6.4    6.6    6.8    6.9    6.9    6.9    7.1    7.1    7.0    7.2    7.3    7.3    7.3    7.5    7.4    7.6
  45--54                                                40.1   41.5   42.8   44.4   45.2   45.5   45.1   45.0   44.8   44.2   43.3   43.4   43.7   43.4   43.2   43.8
  55--64                                                137    139    141    142    143    144    144    144    145    147    149    151    152    152    151    151
  65--74                                                415    420    423    427    433    434    436    435    431    425    422    418    410    404    397    393
  75--84                                                912    909    920    935    945    950    956    961    961    961    961    960    946    940    927    920
  85+                                                   1471   1456   1456   1460   1464   1471   1477   1481   1473   1472   1447   1448   1450   1443   1436   1453
  Total                                                 189    191    194    198    201    202    204    205    205    205    205    205    203    202    200    199
  [**Men**]{.ul}                                                                                                                                                 
  18--44                                                6.0    6.0    6.2    6.3    6.3    6.4    6.6    6.4    6.3    6.5    6.6    6.6    6.7    7.0    6.9    7.1
  45--54                                                48.3   49.7   51.7   53.3   54.0   53.9   53.7   53.1   52.8   51.9   50.9   51.4   51.8   51.0   50.6   50.7
  55--64                                                181    183    185    187    186    186    186    185    187    187    190    191    192    193    191    191
  65--74                                                556    561    559    563    572    571    568    567    558    550    545    539    527    521    510    503
  75--84                                                1190   1174   1178   1183   1187   1185   1187   1189   1188   1182   1180   1177   1162   1149   1137   1127
  85+                                                   2139   2070   2048   2020   1987   1977   1965   1946   1913   1903   1833   1811   1799   1772   1772   1792
  Total                                                 212    212    215    217    219    220    221    222    221    221    221    221    219    218    217    217
  [**Women**]{.ul}                                                                                                                                               
  18--44                                                6.9    7.2    7.4    7.5    7.5    7.5    7.7    7.7    7.9    7.9    8.0    8.0    8.0    7.9    8.0    8.1
  45--54                                                32     33     34     35     36     37     36     37     37     36     35     35     35     36     36     37
  55--64                                                94     96     97     98     99     100    101    102    104    106    108    111    112    112    111    110
  65--74                                                295    300    306    310    313    315    319    318    318    312    311    306    301    294    290    287
  75--84                                                722    727    743    762    776    785    794    799    799    803    804    803    789    785    771    764
  85+                                                   1177   1185   1195   1213   1233   1246   1259   1271   1272   1272   1266   1275   1281   1282   1270   1284
  Total                                                 167    170    175    179    183    185    188    189    189    189    190    190    188    187    184    183

10.1371/journal.pone.0179658.t002

###### Jointpoint analysis of trends in prevalence of ischemic stroke among men and women in Sweden from 1995--2010.
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  Age group (years)    Period 1 Years   APC (95% CI)[^a^](#t002fn001){ref-type="table-fn"}         Period 2 Years   APC (95% CI) [^a^](#t002fn001){ref-type="table-fn"}        Period 3 Years   APC (95% CI) [^a^](#t002fn001){ref-type="table-fn"}
  -------------------- ---------------- ---------------------------------------------------------- ---------------- ---------------------------------------------------------- ---------------- ----------------------------------------------------------
  [**Overall**]{.ul}                                                                                                                                                                            
  18--44               1995--1998       2.1 (0.9 to 3.4)[\*](#t002fn002){ref-type="table-fn"}      1998--2010       0.7 (0.6 to 0.9)[\*](#t002fn002){ref-type="table-fn"}      \-               \-
  45--54               1995--1999       3.3 (2.7 to 4.0)[\*](#t002fn002){ref-type="table-fn"}      1999--2006       -0.7 (-1.1 to -0.4)[\*](#t002fn002){ref-type="table-fn"}   2006--2010       0.1 (-0.6 to 0.7)
  55--64               1995--2004       0.7 (0.5 to 0.8)[\*](#t002fn002){ref-type="table-fn"}      2004--2007       1.3 (-0.4 to 3.0)                                          2007--2010       -0.4 (-1.3 to 0.4)
  65--74               1995--2001       0.9 (0.7 to 1.0)[\*](#t002fn002){ref-type="table-fn"}      2001--2006       -1.0 (-1.2 to -0.7)[\*](#t002fn002){ref-type="table-fn"}   2006--2010       -1.6 (-1.8 to -1.3)[\*](#t002fn002){ref-type="table-fn"}
  75--84               1995--2001       1.0 (0.7 to 1.2)[\*](#t002fn002){ref-type="table-fn"}      2001--2006       0.0 (-0.4 to 0.4)                                          2006--2010       -1.1 (-1.5 to -0.7)[\*](#t002fn002){ref-type="table-fn"}
  ≥85                  1995--2002       0.1 (-0.1 to 0.4)                                          2002--2010       -0.3 (-0.5 to -0.1)[\*](#t002fn002){ref-type="table-fn"}   \-               \-
  Total                1995--2000       1.6 (1.4 to 1.7)[\*](#t002fn002){ref-type="table-fn"}      2000--2006       0.1 (-0.0 to 0.3)                                          2006--2010       -0.8 (-1.0 to -0.6)[\*](#t002fn002){ref-type="table-fn"}
  [**Men**]{.ul}                                                                                                                                                                                
  18--44               1995--2010       1.0 (0.8 to 1.2)[\*](#t002fn002){ref-type="table-fn"}      \-               \-                                                         \-               \-
  45--54               1995--1999       2.8 (2.0 to 3.7)[\*](#t002fn002){ref-type="table-fn"}      1999--2010       -0.7 (-0.9 to -0.5)[\*](#t002fn002){ref-type="table-fn"}   \-               \-
  55--64               1995--2010       0.3 (0.3 to 0.4)[\*](#t002fn002){ref-type="table-fn"}      \-               \-                                                         \-               \-
  65--74               1995--2001       0.5 (0.3 to 0.8)[\*](#t002fn002){ref-type="table-fn"}      2001--2010       -1.4 (-1.5 to -1.3)[\*](#t002fn002){ref-type="table-fn"}   \-               \-
  75--84               1995--2005       0.0 (-0.1 to 0.1)                                          2005--2010       -1.0 (-1.3 to -0.8)[\*](#t002fn002){ref-type="table-fn"}   \-               \-
  ≥85                  1995--2010       -1.2 (-1.4 to -1.1)[\*](#t002fn002){ref-type="table-fn"}   \-               \-                                                         \-               \-
  Total                1995--2000       0.9 (0.7 to 1.1)[\*](#t002fn002){ref-type="table-fn"}      2000--2005       0.0 (-0.2 to 0.2)                                          2005--2010       -0.4 (-0.6 to -0.3)[\*](#t002fn002){ref-type="table-fn"}
  [**Women**]{.ul}                                                                                                                                                                              
  18--44               1995--1997       3.3 (0.4 to 6.3)[\*](#t002fn002){ref-type="table-fn"}      1997--2005       1.0 (0.6 to 1.3)[\*](#t002fn002){ref-type="table-fn"}      2005--2010       0.1 (-0.5 to 0.8)
  45--54               1995--2000       3.1 (2.3 to 3.9)[\*](#t002fn002){ref-type="table-fn"}      2000--2007       -0.7 (-1.3 to -0.2)[\*](#t002fn002){ref-type="table-fn"}   2007--2010       1.2 (-0.5 to 2.9)
  55--64               1995--2003       1.2 (1.1 to 1.3)[\*](#t002fn002){ref-type="table-fn"}      2003--2007       2.1 (1.6 to 2.6)[\*](#t002fn002){ref-type="table-fn"}      2007--2010       -0.6 (-1.1 to -0.1)[\*](#t002fn002){ref-type="table-fn"}
  65--74               1995--2001       1.3 (1.0 to 1.6)[\*](#t002fn002){ref-type="table-fn"}      2001--2005       -0.8 (-1.6 to 0.0)                                         2005--2010       -1.7 (-2.0 to -1.3)[\*](#t002fn002){ref-type="table-fn"}
  75--84               1995--2000       1.9 (1.6 to 2.2)[\*](#t002fn002){ref-type="table-fn"}      2000--2005       0.5 (0.0 to 0.9)                                           2005--2010       -1.1 (-1.4 to -0.8)[\*](#t002fn002){ref-type="table-fn"}
  ≥85                  1995--2002       1.1 (1.0 to 1.3)[\*](#t002fn002){ref-type="table-fn"}      2002--2010       0.1 (-0.1 to 0.2)                                          \-               \-
  Total                1995--2000       2.3 (2.2 to 2.5)[\*](#t002fn002){ref-type="table-fn"}      2000--2006       0.3 (0.1 to 0.5)[\*](#t002fn002){ref-type="table-fn"}      2006--2010       -1.1 (-1.3 to -0.8)[\*](#t002fn002){ref-type="table-fn"}

^a^APC = Annual percentage change

\*Significantly different from zero at α = 0.05.

In the youngest age group of 18--44 years, the prevalence increased with an APC of 2.1% (95% CI 0.9 to 3.4) from 6.4 in 1995 to 6.9 patients per 10,000 population in 1998. The prevalence continued to increase but at a slower pace with an APC of 0.7% (95% CI 0.6 to 0.9) throughout the study and with a final prevalence of 7.6 patients per 10,000 population in 2010. An increase in overall prevalence was observed among those aged 45--54 years with an APC of 3.3% (95% CI 2.7 to 4.0) during 1995--1999 and by 0.7% (95% CI 0.5 to 0.8) among 55--64 years during 1995--2004. For those aged 45--54 years the prevalence decreased (APC: -0.7%, 95% CI -1.1 to -0.4) until 2006, after which it remained stable throughout the study with a final prevalence of 43.8 patients per 10,000 population in 2010. Among 55--64 years, there were no significant changes in prevalence after 2004 and with a final prevalence of 151 patients per 10,000 population in 2010. For those aged 65--74 years, the overall prevalence of IS increased with an APC of 0.9% (95% CI 0.7 to 1.0) from 415 in 1995 to 436 patients per 10,000 population in 2001. This was then followed by a decrease (APC: -1.0%, 95% CI -1.2 to -0.7) until 2006 which continued throughout the study but at higher rate (APC: -1.6%, 95% CI -1.8 to -1.3) and with a final prevalence of 393 patients per 10,000 population in 2010. Among persons aged 75--84 years, the prevalence increased with an APC of 1.0% (95% CI 0.7 to 1.2) from 912 in 1995 to 956 patients per 10,000 population in 2001. The prevalence remained stable until 2006 which was then followed by a decrease (APC: -1.1%, 95% CI -1.5 to -0.7) to 920 patients per 10,000 population in 2010. In the oldest age group ≥85 years, the overall prevalence was estimated as 1471 patients per 10,000 population in 1995 which remained stable until 2002. Afterwards there was a slight decline in prevalence (APC: -0.3%, 95% CI -0.5 to -0.1) throughout the study to 1453 patients per 10,000 population in 2010.

Trends in age- and sex-specific prevalence {#sec012}
------------------------------------------

The overall prevalence of IS in men aged 18 to ≥85 years increased with an APC of 0.9% (95% CI 0.7 to 1.1) from 212 in 1995 to 220 patients per 10,000 population 2000 and then remained stable until 2005, followed by a decrease (APC: -0.4%, 95% CI -0.6 to -0.3) to 217 patients per 10,000 population in 2010 (Tables [1](#pone.0179658.t001){ref-type="table"} and [2](#pone.0179658.t002){ref-type="table"}). Among women the overall prevalence increased with an APC of 2.3% (95% CI 2.2 to 2.5) from 167 in 1995 to185 patients per 10,000 population in 2000. The prevalence rates continued to increase (APC: 0.3%, 95% CI 0.1 to 0.5) but at a slower pace until 2006 and with a prevalence of 190 patients per 10,000 population, then declining with an APC of -1.1% (95% CI -1.3 to -0.8) to 183 patients per 10,000 population in 2010. Trends in the overall prevalence of IS differed markedly by age and sex. In men, the prevalence in those aged 18--44 years increased slightly but continuously with an APC of 1.0% (95% CI 0.8 to 1.2) throughout the study from 6.0 in 1995 to 7.1 patients per 10,000 population in 2010, a relative increase of 18.3% ([Table 1](#pone.0179658.t001){ref-type="table"} and [Fig 1B](#pone.0179658.g001){ref-type="fig"}). The prevalence among those aged 45--54 years increased during the first years with an APC of 2.8%, (95% CI 2.0 to 3.7) until 1999, followed by a slight decrease (APC -0.7, 95% CI -0.9 to -0.5) throughout the study and with a final prevalence of 50.7 patients per 10,000 population in 2010.

![Relative change in the prevalence of IS divided by age groups in A) all patients, B) in men, and C) in women.](pone.0179658.g001){#pone.0179658.g001}

For women, a similar pattern was observed among those aged 18--44 years. Prevalence increased with an APC of 3.3% (95% CI 0.4 to 6.3) from 6.9 in 1995 to 7.4 patients per 10,000 population in 1997. The rates continued to increase from 1997--2005 but at a slower pace (APC: 1.0%, 95% CI 0.6 to 1.3) after which the rates remained stable throughout the study with a final prevalence of 8.1 patients per 10,000 population in 2010, and with a relative increase of 17.4% ([Fig 1C](#pone.0179658.g001){ref-type="fig"}). During 1995--2000 the prevalence among women aged 45--54 years increased with an APC of 3.1% (95% CI 2.3 to 3.9) from 32 to 37 patients per 10,000 population, followed by a slight decrease until 2007 (APC: -0.7%, 95% CI -1.3 to -0.2) and then remained stable throughout the study with a final prevalence of 37 patients per 10,000 population in 2010. The prevalence of IS among men aged 55--64 years increased throughout the study with an APC of 0.3% (95% CI 0.3 to 0.4) from 181 in 1995 to 191 patients per 10,00 population in 2010. Among women aged 55--64 years there was an initial increase (APC: 1.2%, 95% CI 1.1 to 1.3) in prevalence from 94 in 1995 to 104 patients per 10,000 population in 2003. This was then followed by a steeper increase (APC: 2.1%, 95% CI 1.6 to 2.6), reaching a peak in 2007, after which there was a minor decline (APC:-0.6%, 95% CI -1.1 to -0.1) and with a final prevalence of 110 patients per 10,000 population in 2010. The prevalence among those aged 65--74 years increased with an APC of 0.5% (95% CI 0.3 to 0.8) in men from 556 in 1995 to 568 patients per 10,000 population in 2001. Corresponding results for women was 295 to 319 patients per 10,000 population and with an APC of 1.3% (95% CI 1.0 to 1.6) during 1995--2001. The rates then decreased in men (APC: -1.4%, 95% CI -1.5 to -1.3) throughout the study, but not in women where it remained stable until 2005, followed by a decline (APC: -1.7%, 95% CI -2.0 to -1.3) and with a final prevalence of 503 and 287 patients per 10,000 population, respectively, in 2010. From 1995--2000 the prevalence rate of IS among those aged 75--84 years increased in women (APC: 1.9%, 95% CI 1.6 to 2.2) from 722 to 799 patients per 10,000 population while it remained stable in men. The rates in women continued to increase but at a slower pace until 2005 (APC: 0.5%, 95% CI 0.0 to 0.9). After 2005, the rates decreased with an APC of -1.0% (95% CI -1.3 to -0.8) in men and by -1.1% (95% CI -1.4 to -0.8) in women throughout the study, with a final prevalence of 1127 and 764 patients per 10,000 population, respectively, in 2010. In the oldest age group of ≥85 years, the prevalence of IS decreased with an APC of -1.2% (95% CI -1.4 to -1.1) throughout the study in men from 2139 in 1995 to 1792 patients per 10,000 population in 2010. Among women the prevalence increased with an APC of 1.1% (95% CI 1.0 to 1.3) from 1177 in 1995 to 1271 patients per 10,000 population in 2002 after that the rates of IS remained stable, with a final prevalence of 1284 patients per 10,000 population, in 2010.

Discussion {#sec013}
==========

Our study shows that the overall number of patients who were hospitalized with IS increased by 12.5% in men and 18.0% in women from 1995--2010. An overall increase in prevalence of IS was observed during most of the mid to late 1990s, but leveled off after 2000 and remained stable until 2006, followed by a slight decline (APC: -0.8%, 95% CI -1.0 to -0.6) and with a final prevalence of 199 patients per 10,000 population in 2010 (Tables [1](#pone.0179658.t001){ref-type="table"} and [2](#pone.0179658.t002){ref-type="table"}). Age-specific trends in prevalence markedly differed. In the youngest age group of 18--44 years, the prevalence of IS increased throughout the study period. However, in those aged 45--54 years the prevalence increased from 1995--1999, followed by a slight decline (APC: -0.7%, 95% CI -1.1 to -0.4) until 2006 and then remained stable at 43.8 patients per 10,000 population in 2010. In the oldest age group of ≥85 years the overall prevalence of IS remained stable during the first years of the study, after 2002 there was a slight decline (APC: -0.3%, 95% CI -0.5 to -0.1) until 2010 with a final estimate of 1453 patients per 10,000 population.

Most studies on stroke prevalence have only considered overall stroke while we estimated IS only. In an Italian study, the overall prevalence of stroke in persons aged ≥15 years was estimated as 1.47% in 2004, but this was based on comparatively few cases \[[@pone.0179658.ref013]\]. In England, Scotland, and Wales, the prevalence was 1.7% in 2006/2007, while in Australia, the estimate prevalence in 2009 was 1.9% in men and 1.3% in women \[[@pone.0179658.ref014],[@pone.0179658.ref015]\]. Canada reported a prevalence of stroke of 1.14% in 2009/2010, and in United States, stroke prevalence remained stable at 2.6% from 2006--2010 \[[@pone.0179658.ref008],[@pone.0179658.ref016]\]. Previous studies were either based on specific regions, self-reported, a national survey, or conducted only for a short period of time \[[@pone.0179658.ref013],[@pone.0179658.ref015],[@pone.0179658.ref016]\]. We aimed to investigate trends in the prevalence of IS for a whole nation over time based on national hospital records, based on the net effect of the incidence of IS and mortality for each year. This provides the absolute number of patients with IS and enabled us to estimate trends in prevalence of IS. We found that the overall prevalence of IS in Sweden increased during the mid to late 1990s until the beginning of the 2000s, and then remained stable until 2006 after which it declined slightly until 2010 (199 per 10,000 population), but with varying trends between age groups ([Table 1](#pone.0179658.t001){ref-type="table"}). Decline in overall prevalence of IS might to some extent be explained by improvements in treatments and changes in cardiovascular risk factors over time e.g. lower blood pressure levels and smoking rates \[[@pone.0179658.ref017]--[@pone.0179658.ref020]\]. This might be explained by dietary changes and better antihypertensive treatment in the general population over time but also due to intervention campaigns and implemented smoking bans in public spaces. Additionally, decreases in cholesterol levels have been observed in Sweden for the past years which explained most of the decline in coronary heart disease mortality in Sweden \[[@pone.0179658.ref020]\]. Notably, the overall prevalence rate in the youngest age groups steadily increased throughout the study ([Table 2](#pone.0179658.t002){ref-type="table"}). A possible explanation for the increase in prevalence could be due to better diagnostic methods over time such as the use of magnetic resonance imaging. However, this would not have affected only young people in whom we observed the most marked rise in prevalence of IS. Computed tomography scan (CT) has been widely used during the study period to distinguish between ischemic and hemorrhagic stroke. According to a recent study from the Swedish Stroke Register (Riks-Stroke) a majority of stroke patients are examined with CT (\>98%) \[[@pone.0179658.ref021]\]. The overall prevalence of IS was slightly higher in men than in women in all age groups. Similar findings were reported in Western Australia and Canada, but not in the USA, which reported a slightly higher proportion of women in people aged \<60 years \[[@pone.0179658.ref008],[@pone.0179658.ref015],[@pone.0179658.ref016]\]. Our results of an increasing prevalence of IS in the younger age groups are in accordance with previous findings of an increasing incidence trend of IS in younger adults \[[@pone.0179658.ref022]--[@pone.0179658.ref024]\]. The reasons for this are not known, but could potentially be due to increasing sedentary lifestyle and obesity but also to demographic changes in population \[[@pone.0179658.ref025], [@pone.0179658.ref026]\]. Generally, the greatest increase in prevalence of IS in men and women occurred during the mid to late 1990s, followed by a stabilized or declining rate until the end of the study period. Although the prevalence of IS in some age groups remained stable or declined for a few years, the absolute number of patients increased over time, likely due to demographic changes with more people surviving into old age but also because of improved primary and secondary treatments in stroke ([S2 Fig](#pone.0179658.s002){ref-type="supplementary-material"}). We have demonstrated improved survival after ischemic stroke in IS patients aged 55 and younger, which likely is applicable to older patients as well \[[@pone.0179658.ref003]\]. The largest proportional increase was observed among those aged 55--64 years and ≥85 years because of the growing numbers of people in the two age groups in the general population. Additionally, recent advances and developments in the healthcare system have led to an overall improvement in survival with improvements in medical treatment and secondary prevention (e.g., increased use of anticoagulation treatment among older people after a stroke) \[[@pone.0179658.ref027]--[@pone.0179658.ref030]\]. Because stroke is strongly correlated with age, quantifying the numbers of stroke is an important task for future healthcare planning.

Strengths and limitations {#sec014}
-------------------------

There are limitations and strengths to our study. To investigate trends in prevalence over time, large populations are often needed to identify a sufficient amount of people with IS. Therefore, the main strength of our study is the use of data from an entire nation. Because of our unique personal identification numbers, all people could be followed throughout the whole study period with virtually no loss to follow-up. This enabled study of age-specific trends in prevalence over a long time in men and women separately. Limitations include the lack of externally validated stroke diagnoses over time. However, previous studies on the use of principal diagnosis from the Swedish IPR have shown a high validity of many cardiovascular diagnoses, including stroke, especially after 2000 \[[@pone.0179658.ref031], [@pone.0179658.ref032]\]. A limitation in the present study is the lack of information on diagnostic methods because improved medical imaging modalities over time could increase detection rates of IS. However, CT scan has been widely used during the study period and is still the most common method in the evaluation of stroke and accordingly changes in detection rates are unlikely to explain the trends that we observed, or the variation between age groups \[[@pone.0179658.ref021]\].

Conclusions {#sec015}
===========

In conclusion, the overall prevalence of hospitalized patients with IS has increased for the past years in Sweden but at different rates over time. In most age groups, the prevalence of IS increased during the mid to late 1990s and then declined or remained stable, except in the youngest age groups where the prevalence increased throughout the study. Additionally, the absolute number of patients with IS has increased in most age groups from 1995--2010, especially in those aged 55--64 years and ≥85 years, which could mainly be explained by demographic factors. If this trend continues into the future, it will cause additional strain to the healthcare system.

Supporting information {#sec016}
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###### Relative change in number of patients hospitalized with IS from 1995--2010 by age group in A) all patients, B) in men and C) women only.

(TIF)

###### 

Click here for additional data file.

###### Relative demographic change in population size from 1995--2010 in the Swedish population by age groups.

(TIF)
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Click here for additional data file.

###### Number of patients hospitalized with an ischemic stroke divided by age groups, sex and calendar year from 1995--2010.

(DOCX)

###### 

Click here for additional data file.
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